# Impact of Rosuvastatin Doses on LDL Levels, CPK Levels and Aspartate Aminotransferase Levels

> **NCT06910098** · NA · COMPLETED · sponsor: **Central Park Medical College** · enrollment: 195 (actual)

## Conditions studied

- LDL - Low Density Lipoprotein Receptor Disorder
- Rosuvastatin

## Interventions

- **DRUG:** Rosuvastatin
- **DRUG:** Rosuvastatin
- **DRUG:** Rosuvastatin

## Key facts

- **NCT ID:** NCT06910098
- **Lead sponsor:** Central Park Medical College
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-12-01
- **Primary completion:** 2024-06-30
- **Final completion:** 2024-08-31
- **Target enrollment:** 195 (ACTUAL)
- **Last updated:** 2025-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06910098

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06910098, "Impact of Rosuvastatin Doses on LDL Levels, CPK Levels and Aspartate Aminotransferase Levels". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT06910098. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*